PharmTech News

Articles

FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.

Sanofi Gets Priority Review Status for sBLA Seeking Approval of Sarclisa in Combination Therapy for Multiple Myeloma

Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

FDA Approves Interchangeable Biosimilar to Soliris

Feliza Mirasol is the science editor for 

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.  

Johnson & Johnson to Acquire Global Rights to Numab Therapeutics’ Bispecific Antibody for Atopic Dermatitis in $1.25 Billion Deal

The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.

Integrated Biosciences Collaborates with Illumina Ventures Labs Collaborate on Novel Therapeutics

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases. 

Biogen to Acquire HI-Bio in Deal Worth Potentially Up to $1.8 Billion

The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.

Bristol Myers Squibb Plans 10-Year Strategy to Expand Access to Medications

The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.

AstraZeneca Plans $1.5 Billion ADCs Facility in Singapore

At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.

Embedding Sustainability in Drug Delivery through Industry Consensus at CPHI NA

The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.

Regeneron Presents Update on Gene Therapy for Genetic Deafness at ASGCT

The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.

Bio/Pharma News